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Objectives: In order to create a suitable model for high-throughput drug screening, a Giardia lamblia
WB C6 strain expressing Escherichia coli glucuronidase A (GusA) was created and tested with respect
to susceptibility to the anti-giardial drugs nitazoxanide and metronidazole.
Methods: GusA, a well-established reporter gene in other systems, was cloned into the vector
pPacVInteg allowing stable expression in G. lamblia under control of the promoter from the glutamate
dehydrogenase (gdh) gene. The resulting transgenic strain was compared with the wild-type strain in a
vitality assay, characterized with respect to susceptibility to nitazoxanide, metronidazole and—as
assessed in a 96-well plate format—to a panel of 15 other compounds to be tested for anti-giardial
activity.
Results: GusA was stably expressed in G. lamblia. Using a simple glucuronidase assay protocol, drug
efficacy tests yielded results similar to those from cell counting.
Conclusions: G. lamblia WB C6 GusA is a suitable tool for high-throughput anti-giardial drug
screening.
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Introduction
During recent decades, novel anti-infective drugs have regained
importance because of increasing resistance to well-established
antibiotics and due to the emergence of new infectious dis-
eases.1 Giardia lamblia, for instance, responsible for several
million cases of persistent diarrhoea worldwide, is currently
treated with metronidazole, representing the main drug so far to
be available on a global scale.2 The thiazolide nitazoxanide is a
good alternative.3,4 In case of resistance formation, albenda-
zole5,6 or isoflavones7 are other options.
In order to find novel drug candidates, a high-throughput
screening system is required. Present screening methods include
counting of trophozoites,8,9 incorporation of [3H]thymidine10 or
a vitality assay based on the reduction of resazurin (Alamar
Blue) quantified by fluorimetry.11 These methods are time-
consuming or need expensive equipment. A more suitable
method would be the use of a reporter strain as shown for
instance for Toxoplasma gondii expressing b-galactosidase.9,12
Here, we present a short study describing the construction of a
transgenic Giardia cell line expressing Escherichia coli glucuro-
nidase A (GusA), and first drug efficacy tests using a protocol
adapted to a 96-well format.
Materials and methods
Tissue culture media, biochemicals and drugs
If not otherwise stated, the biochemical reagents were from Sigma
(St Louis, MO, USA). All compounds tested were kept as 100 mM
stock solutions in DMSO at 2208C.
Culture of Giardia trophozoites and drug treatment assays
Trophozoites from G. lamblia WB clone C6 were grown under
anaerobic conditions in 10 mL culture tubes (Nunc, Roskilde,
Denmark) or in 96-well-plates containing modified TYI-S-33
medium as described previously.7,8 For drug treatment assays, cul-
tures with confluent trophozoite layers were incubated on ice for
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15 min. Suspended motile trophozoites were counted (Neubauer
chamber, 200) and 5103 trophozoites/mL were inoculated into
24-well plates (1 mL per well) or 96-well plates (0.2 mL per well)
in the presence of compound or a solvent control (DMSO). The
plates were incubated in an anaerobic chamber for 72 h, and
attached trophozoites were counted by light microscopy7 or pro-
cessed further for a glucuronidase assay or for a resazurin (Alamar
Blue) vitality assay as described previously.11
Cloning of GusA
In a first round, GusA was cloned into the His tag expression vector
pET151 directional TOPO (Invitrogen, Carlsbad, CA, USA); the
primers pGusF and pGusR (Table 1) were created for the amplification
of a 1811 bp product encoding the GusA polypeptide with four
additional bases at the 50 end allowing directional cloning as pre-
viously described.13 For amplification by PCR, genomic DNA was
extracted from 108 E. coli TOP 10 cells using the DNeasy kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions. The
resulting DNA was diluted 10 in ultrapure water. The PCR was per-
formed using pfu DNA polymerase (Promega, Madison, WI, USA) as
described. The resulting 1811 bp product was inserted into the pET151
vector using the respective cloning kit according to the manufacturer,
and the vector was transformed into E. coli TOP 10 cells (Invitrogen).
Positive clones were expressed in E. coli BL21 as described.
A clone with appropriate expression of the recombinant enzyme
was selected by purification of the recombinant enzyme followed by
a glucuronidase assay as described below and then used for the
re-cloning of gusA into the giardial vector pPacVInteg using the
XbaI and PacI sites for integration.14 For this purpose, a forward
primer was designed starting with the XbaI site followed by the glu-
tamate dehydrogenase promoter, a strong promoter as previously
characterized in G. lamblia.15 In the reverse primer, a sequence
encoding an HA tag was included before the PacI site (Table 1).
PCRs were performed using the pfu polymerase as described above,
and fragments were cloned into the Zero Blunt TOPO vector
(Invitrogen) according to the manufacturer’s instructions. Inserts
were cut out with XbaI and PacI and ligated into pPacV thus yield-
ing pPacV-GusA. Prior to transfection, the vector pPac-GusA was
linearized by digestion with SwaI in order to allow chromosomal
integration of the transgene by homologous recombination. Then,
transfection of G. lamblia WB C6 and selection of stable transfec-
tants (containing GusA integrated in the genome) by resistance to
the antibiotic puromycin was performed as previously described.14
Glucuronidase assay
Glucuronidase was assayed in 50 mM NaHPO4, pH 7, containing
5 mM dithiothreitol, 1 mM EDTA and 0.1% Triton X-100 (assay
buffer).16 For assays in cuvettes, trophozoites were suspended in
1.5 mL of assay buffer. The reaction was started by adding 15 mL of
100 mM p-nitrophenyl-glucuronide (1 mM final concentration). At
various timepoints, 0.2 mL aliquots were removed and mixed with
0.8 mL of 0.2 M Na2CO3 (stop solution) in order to stop the reaction
and enhance colour development. For assays in 96-well microtitre
plates, plates with trophozoites were washed once with PBS pre-
warmed at 378C in order to remove unattached trophozoites and
debris. Then, cells were suspended in 50 mL of assay buffer contain-
ing the substrate and incubated at 378C. In the control wells, the
reaction was stopped immediately by adding 200 mL of stop sol-
ution. In the other wells, the reaction was stopped depending on
colour formation. Absorption was then read at 410 nm and activity
calculated using the extinction coefficient 18.3 M21cm21. T
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More suitable for high-throughput screening was the following
assay system based on the formation of an insoluble, blue product.
The assay mixture consisted of 50 mM NaHPO4 containing 1 mM
EDTA, 50 mM potassium ferrocyanide, 20% methanol and 1 mM
5-bromo-4-chloro-3-indoyl-b-D-glucuronide cyclohexylammonium
salt (X-glucuronide) and was applied to trophozoites grown in
microtitre plates as described above (100 mL per well).17 The colour
formation was monitored visually and by reading the absorption at
625 nm at various timepoints.
Statistics
IC50 values were calculated after the logit-log-transformation of the
relative growth (RG; control¼1) according to the formula ln[RG/
(12RG)]¼aln(drug concentration)þb followed by regression
analysis using the corresponding software tool contained in the
Excel software package (Microsoft, Seattle, WA, USA).
Results and discussion
GusA can be expressed in G. lamblia
G. lamblia WB C6 trophozoites were transfected with
pPacV-GusA and stable transfectants were selected by resistance
to puromycin (see above). After removal of puromycin, cells
were grown for .10 generations. As a control, trophozoites
were transformed with pPacV–GFP (expressing green fluor-
escent protein) and cultivated in parallel. Three independent cul-
tures were harvested and glucuronidase was assayed. Extracts
from GFP-transformed trophozoites yielded a background
activity close to zero. Extracts from GusA-transformed cells,
however, had strong glucuronidase activity with a linear increase
of absorption between 0 and 1 (Figure 1). Thus, GusA could be
expressed in G. lamblia and was stable for .10 generations.
1.2
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Figure 1. Glucuronidase activity in G. lamblia WB C6 expressing E. coli
GusA or GFP as a control. Confluent cultures were harvested and suspended
in GusA assay buffer (106 trophozoites/mL). Enzyme reactions were initiated
by adding p-nitrophenyl-glucuronidase. At various timepoints, aliquots were
removed and added to stop solution. Mean values and standard errors
(smaller than symbols) correspond to three independent cultures per clone.
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Figure 2. Comparison of G. lamblia WB C6 expressing E. coli GusA with
its corresponding wild-type (wt) using a vitality assay. Plates (96-well) were
inoculated with 2102 trophozoites of wt or GusA trophozoites per well and
grown in the presence of metronidazole at various concentrations. After 72 h,
cell growth was monitored by a vitality assay based on the reduction of
resazurin (Alamar Blue) to a pink product that was assayed fluorimetrically.
Mean values of the RFU normalized to the control values (+SE) are given
for six replicates.
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Figure 3. Suitability of G. lamblia WB C6 GusA for drug efficacy assays.
Plates (96-well) were inoculated with 2102 trophozoites per well and
grown in the presence of nitazoxanide (NTZ) or metronidazole (MET) at
various concentrations. After 72 h, cell growth was monitored either by
counting (a) or by a glucuronidase assay based on the hydrolysis of
p-nitrophenyl-glucuronide (b). Mean values+SE are given for six replicates.
Table 2. IC50 values of nitazoxanide (NTZ) and metronidazole
(MET) for transgenic G. lamblia WB C6 GusA
Treatment IC50 (mM)
NTZ counting 2.7 (1.2)
MET counting 5.9 (1.1)
NTZ Gus 3.2 (1.2)
MET Gus 6.3 (1.1)
The values were calculated from the mean values either determined by
counting or by a glucuronidase assay (Gus) as shown in Figure 2. Standard
deviations are noted in parentheses.
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G. lamblia WB C6 wild-type and GusA transgenic strain
exhibit similar vitality patterns in drug efficacy tests
A vitality assay based on the reduction of resazurin (Alamar
Blue) quantified by fluorimetry had previously been established
for testing drug efficacy against G. lamblia trophozoites.11 It
was thus tempting to compare trophozoites of G. lamblia WB
C6 wild-type and GusA in this assay system. In order to investi-
gate whether these trophozoites differ with respect to their
metabolism of Alamar Blue, trophozoites of both strains were
harvested, counted and subjected to an Alamar Blue assay at six
different cell densities (ranging from 106 to 102 cells). The
results were 3.4+0.4 relative fluorescence units (RFU)/cell for
the wild-type and 4.1+0.7 RFU/cell for the GusA strain. In a
second experiment, trophozoites of both strains were grown in
96-well microtitre plates in the presence of various concen-
trations of metronidazole. After 72 h, vitality was determined by
an Alamar Blue assay. Both strains gave very similar IC50
values, namely 3.1+1.1 mM for the wild-type and 4.4+1.2 mM
for the GusA strain (Figure 2).
G. lamblia WB C6 GusA is suitable for drug efficacy tests
In order to investigate whether G. lamblia WB C6 GusA is suit-
able for drug efficacy tests in the microtitre format, trophozoites
were grown in 24-well or 96-well microtitre plates in the pres-
ence of various concentrations of nitazoxanide and metronida-
zole, two drugs with proven effectiveness against G. lamblia.8,10
After 72 h, growth was determined either by counting (24-well
plates) or by a glucuronidase assay (96-well plates) adapted to
the microtitre format. Both measurements yielded nearly identi-
cal results (Figure 3) with IC50 values of 3 mM of nitazoxa-
nide and 6 mM of metronidazole (Table 2). Both values were
in good agreement with previously published data obtained with
untransfected WB C6.8 The fact that these IC50 values were
slightly higher than the ones found with the Alamar Blue assay
is in good agreement with previously published results.11 Thus,
G. lamblia WB C6 GusA is a suitable strain for use in drug
testing.
In order to provide a proof of concept for the suitability of
the transgenic strain for high-throughput drug screening pur-
poses, a small screen was performed including compounds with
known efficacy and some antiparasitic drugs with unknown effi-
cacy against G. lamblia. For this screen, glucuronidase activity
was detected using X-glucuronide. X-glucuronide as well as the
resulting blue, insoluble product were stable for at least several
weeks thus providing clear-cut results that were easily documen-
ted by photographs or simply by storing the dried plates.
Concerning compounds with known efficacy against G. lamblia,
such as the thiazolide tizoxanide and some of its derivatives, the
screen provided similar results to those of previous reports.8,10
Moreover, the screen showed that the antimalarial drug meflo-
quine inhibited trophozoite growth, as did dinitrotoluol, a sub-
strate of a previously described G. lamblia nitroreductase.13
Interestingly, the glucuronide of tizoxanide, which was ineffec-
tive against G. lamblia WB C6, showed some activity against
WB C6 GusA, most likely due to a cleavage of the glucuronide
due to the highly expressed glucuronidase (Table 3).
Taken together, G. lamblia WB C6 expressing GusA as a
reporter gene constitutes a suitable tool for high-throughput anti-
giardial drug screening.
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Table 3. Application of G. lamblia WB C6 GusA for anti-giardial drug screening
Compound Reference(s) Effective against G. lamblia Glucuronidase activity (percentage of control)
Nitazoxanide 6,8,10 yes 0+0
Tizoxanide 8,10 yes 0+0
Tizoxanide glucuronide 8,10 no 32+6
RM4802 8 yes 0+0
RM4803 8 no 83+8
RM4805 8 yes 2+1
RM4806 8 no 65+9
RM4807 8 yes 0+0
Metronidazole 6,8,10 yes 0+0
Albendazole 5,6 yes 0+0
Praziquantel ? 81+8
Pentamidine DB750 18 ? 68+3
Formononetin 7 yes 0+0
Daidzein 7 yes 0+0
Genistein 7 yes 0+0
Mefloquine 19 ? 0+0
Dinitrotoluol 13 ? 6+1
Plates (96-well) were inoculated with 2102 trophozoites per well and grown in the presence of the drugs listed (50 mM). After 72 h, growth of cells was
monitored by a glucuronidase assay based on the formation of an insoluble, blue product from X-glucuronide. Glucuronidase activity is expressed as a
percentage of the control mean value obtained in the presence of DMSO. Means+SE are given for four replicates.
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